Healthcare
On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.
Surface Oncology announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company.
Novo Seeds, the early stage investment arm of Novo Holdings, wholly owned by the Novo Nordisk Foundation, announced that its advisory unit, BiOrigin, has appointed several seasoned entrepreneurs to its team.
Kura Oncology, Inc. announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 12:00 p.m. ET / 9:00 a.m. PT.
Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia
New Facility for Maravai’s TriLink BioTechnologies Set to Supercharge messengerRNA Therapeutics Development
Philadelphia, PA – Oncoceutics, Inc. announced that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24th Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona.
Series A round lead investors NordicNinja and Industrifonden to support Combinostics as they scale to US and Asia
Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of the G-protein coupled receptor dopamine receptor D2 by Oncoceutics’ lead candidate imipridone, ONC201.
KidneyX seeks breakthrough solutions to transform kidney care
PRESS RELEASES